Pamidronate disodium pentahydrate
(Synonyms: 帕米膦酸二钠) 目录号 : GC36846
Pamidronate Disodium (CGP 23339AE) is a nitrogen containing bisphosphonate, used to prevent osteoporosis.
Cas No.:109552-15-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pamidronate Disodium (CGP 23339AE) is a nitrogen containing bisphosphonate, used to prevent osteoporosis.
Pamidronate increases OPG mRNA levels and protein secretion by hOB by up to 2- to 3-fold in a dose-dependent fashion with a maximum effect at 1 ?M after 72 hours. Artemisinin prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production. Pamidronate induces type I collagen secretion and alkaline phosphatase activity by 2-fold. [1] Pamidronate has a more pronounced calcium-lowering action than etidronate (etidronic acid) and clodronate (clodronic acid) and provides a longer period of normocalcaemic remission. [2] Pamidronate (APD) dose-dependently inhibits resorption of calcium phosphate films by equine OCLs with an IC(50) of 0.58 μM in one horse. Pamidronate also dose-dependently inhibits the number of OCLs present in BM cultures after 7 days. [3]
Pamidronate administration significantly suppresses this increase below the control level in the tibia and distal femur of oophorectomized rats. Pamidronate significantly increases bone density and ash weight in both sham-operated and oophorectomized rats. [4] Pamidronate inhibits all significant effects of growth hormone (GH) and it also decreases the IGF-I levels in rats treated with growth hormone (GH). Pamidronate itself results in increased the bone density and ash weight of the tibia and decreased urinary DPD excretion. [5]
[1] Viereck V, et al. Biochem Biophys Res Commun,?002, 291(3), 680-686. [2] Fitton A, et al. Drugs,?991, 41(2), 289-318. [3] Gray AW, et al. Res Vet Sci,?002, 72(2), 105-113.
| Cas No. | 109552-15-0 | SDF | |
| 别名 | 帕米膦酸二钠 | ||
| Canonical SMILES | OC(P([O-])(O)=O)(CCN)P([O-])(O)=O.O.O.O.O.[Na+].[Na+].O | ||
| 分子式 | C3H9NNa2O7P2 | 分子量 | 279.03 |
| 溶解度 | Water: 7.14 mg/mL (19.34 mM); DMSO: < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5838 mL | 17.9192 mL | 35.8384 mL |
| 5 mM | 0.7168 mL | 3.5838 mL | 7.1677 mL |
| 10 mM | 0.3584 mL | 1.7919 mL | 3.5838 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。